Complete RLYB Stock Valuation Analysis
Comprehensive intrinsic value analysis using 1 different methodologies
RLYB Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 8 peer companies in Healthcare
P/E Ratio
$-10.41
-3543.5%
Peer Median: 9.7x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.0x
P/S Ratio
$0.30
+0.0%
Peer Median: 14.8x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for RLYB's business model and current situation.
Multiple Comparison
| Multiple | RLYB Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -0.3x | 9.7x | 9.7x | -102.9% | Undervalued |
| EV/EBITDA | -Infinityx | 0.0x | 0.0x | -Infinity% | Undervalued |
| P/S Ratio | 14.8x | 14.8x | 8.9x | 0.0% | Fair Value |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 9.7x | -18.0x | 31.6x | |
| $0.01B | 0.0x | 0.0x | 34.5x | |
| $0.01B | 0.0x | 0.0x | 36.1x | |
| $0.01B | 0.0x | 0.0x | 14.8x | |
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 0.0x | 0.0x | 71.1x | |
| $0.02B | 0.0x | 0.0x | 3.0x |